<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686163</url>
  </required_header>
  <id_info>
    <org_study_id>NGF-ischemic stroke</org_study_id>
    <nct_id>NCT03686163</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke</brief_title>
  <official_title>Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke remains one of the leading causes of death and adult disability worldwide. Yet,&#xD;
      currently, the only accepted treatment for acute ischemic stroke(AIS) is recanalization of&#xD;
      occluded arteries. Thrombolysis with tissue plasminogen activator, limited by its narrow&#xD;
      therapeutic time window and the concern of hemorrhagic complication, is still uncommon in&#xD;
      use. The other approach is to try to impede the ischemic cascade by targeting various&#xD;
      components of the cascade that are deemed to be of importance, namely, a neuroprotection&#xD;
      strategy.&#xD;
&#xD;
      Nerve growth factor (NGF) plays extensive roles in preventing ischemic injury. Besides that,&#xD;
      it is also involved in neurogenesis of the central nervous system (CNS). In addition, the&#xD;
      levels of NGF protein and messenger RNA significantly decreased in the CNS at the first few&#xD;
      hours and returned to normal levels several days later after middle cerebral artery occlusion&#xD;
      (MCAO) in animal models. These observed results suggested that NGF was demanded in ischemic&#xD;
      brain injury, but endogenous NGF is insufficient for the requirement and delivering exogenous&#xD;
      ones will be blocked in entering into the CNS by the blood-brain barrier (BBB).&#xD;
      Intracerebroventricular or intracerebral injection of NGF or grafting of NGF-producing cells&#xD;
      may be less practicable due to invasiveness and safety concerns.&#xD;
&#xD;
      Intranasal (IN) administration is a noninvasive and acceptable delivery strategy for drugs&#xD;
      bypassing BBB and can deliver NGF to the CNS, which has been proved to show neuroprotective&#xD;
      effects on brain injury.&#xD;
&#xD;
      The effects of intranasal NGF in human ischemic stroke is still controversial that need&#xD;
      further evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized, double-blind, placebo-controlled trail of NGF, starting&#xD;
      between 24 to 72 hours post acute ischemic stroke, continuing for 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a favorable neurological function</measure>
    <time_frame>at 90 days post-treatment</time_frame>
    <description>The primary outcome is determined as a favorable neurological function which is defined as Modified Rankin Scale(mRS) score of 0-3</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>IN-NGF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerve Growth Factors</intervention_name>
    <description>the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks</description>
    <arm_group_label>IN-NGF group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18years;&#xD;
&#xD;
          2. Acute ischemic stroke consistent within 72 hours;&#xD;
&#xD;
          3. Written informed consent from patient or surrogate, if unable to provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Premorbid mRS ≥ 3 points;&#xD;
&#xD;
          2. Currently in pregnant or lactating;&#xD;
&#xD;
          3. Allergy to NGF;&#xD;
&#xD;
          4. Current participation in another investigation drug or device study;&#xD;
&#xD;
          5. Life expectancy less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinfeng Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurology, Jinling Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Xinfeng Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic stroke</keyword>
  <keyword>Nerve Growth Factor</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Neurological Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

